Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 18/20 | 0.85 |
| ▸ | MAPK8 | P45983 | 14/20 | 0.85 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16799975 | 0.89 | MAPK10 (0.74) | MAPK10MAPK8MAPK9MAPK13MAPK12 | |
| SCHEMBL16802813 | 0.89 | MAPK10 (0.74) | MAPK10MAPK8MAPK9 | |
| SCHEMBL16802647 | 0.89 | MAPK10 (1.00) | MAPK10MAPK8MAPK9MAPK13MAPK12 | |
| SCHEMBL16802818 | 0.88 | MAPK10 (0.85) | MAPK10MAPK8MAPK9MAPK13MAPK12 | |
| SCHEMBL16802814 | 0.87 | MAPK10 (0.72) | MAPK10MAPK8MAPK9 | |
| SCHEMBL16799590 | 0.87 | MAPK10 (0.71) | MAPK10MAPK8MAPK9MAPK13MAPK12 | |
| SCHEMBL16802816 | 0.87 | MAPK10 (0.74) | MAPK10MAPK8MAPK9MAPK13MAPK12 | |
| SCHEMBL16802829 | 0.86 | MAPK10 (1.00) | MAPK10MAPK8MAPK9MAPK13MAPK12 | |
| SCHEMBL16802760 | 0.85 | MAPK10 (0.75) | MAPK10MAPK8MAPK9MAPK13MAPK12 | |
| SCHEMBL16802684 | 0.85 | MAPK10 (1.00) | MAPK10MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | MAPK10 31/4885MAPK8 55/4885MAPK9 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.